Nirmatrelvir plus ritonavir in COVID-19: a profile of its use.

ABSTRACT: Oral nirmatrelvir plus ritonavir (Paxlovid^™) is an effective treatment option for coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nirmatrelvir inhibits the main protease of SARS-CoV-2, with ritonavir acting as a pharmacokinetic booster. In the phase II/III EPIC-HR trial, nirmatrelvir plus ritonavir reduced the risk of progression to severe COVID-19 in symptomatic, unvaccinated, non-hospitalized adults with mild-to-moderate COVID-19 at high risk for progression to severe disease. The incidence of COVID-19-related hospitalization or death through day 28 was significantly lower with nirmatrelvir plus ritonavir than with placebo. The efficacy of nirmatrelvir plus ritonavir has also been demonstrated in the real-world setting. Nirmatrelvir plus ritonavir is generally well tolerated, with most adverse events being of mild or moderate severity.

Supplementary information

The online version contains supplementary material available at 10.1007/s40267-022-00971-1.

SUBMITTER: Blair HA 

PROVIDER: S-EPMC9734504 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature